Kidney protection is extremely important for diabetes sufferers. Recently, canagliflozin became the first SGLT-2 inhibitor in Switzerland to receive a marketing authorization extension to reduce the risk of progression to diabetic kidney disease in adult patients with type 2 diabetes mellitus and albuminuria.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Severe asthma
Check diagnosis and initiate phenotype-based therapy
- Chronic wounds
State-of-the-art wound management: pioneering innovations
- Allergic rhinitis
International consensus paper summarizes important facts
- Obesity
Possibilities of nutritional therapy
- Headache treatment
The therapy of migraine
- Uveal melanoma
Development of a CAR T-cell therapy for uveal melanoma
- Electrolyte disturbance
Hyponatremia in the outpatient setting
- Study report: Risk factors for hand eczema